BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann Oncol. 2017;28:2860-2865. [PMID: 29045560 DOI: 10.1093/annonc/mdx403] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 19.7] [Reference Citation Analysis]
Number Citing Articles
1 Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97. [PMID: 32553146 DOI: 10.1016/S2468-1253(20)30014-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Domblides C, Gross-Goupil M, Ravaud A, Poullenot F, Daste A. Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. Immunotherapy 2021;13:741-4. [PMID: 33906378 DOI: 10.2217/imt-2020-0282] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 2020;76:233-43. [PMID: 31361907 DOI: 10.1111/his.13963] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
4 Roosenboom B, Horjus Talabur Horje CS, Smids C, Leeuwis JW, van Koolwijk E, Groenen MJM, Wahab PJ, van Lochem EG. Distribution of mucosal PD-1 expressing T cells in patients with colitis of different etiologies. Scand J Gastroenterol 2021;56:671-9. [PMID: 33779456 DOI: 10.1080/00365521.2021.1906316] [Reference Citation Analysis]
5 Shindiapina P, Alinari L. Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. Ther Adv Hematol 2018;9:89-105. [PMID: 29623180 DOI: 10.1177/2040620718761777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:1393-1403.e1. [PMID: 32007539 DOI: 10.1016/j.cgh.2020.01.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
7 Sun L, Arbesman J, Piliang M. Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. Arch Dermatol Res 2021;313:1-10. [PMID: 32519001 DOI: 10.1007/s00403-020-02094-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Damato A, De Marco L, Serra S, Larocca M, Arias AG, Rondini E, Pinto C. Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report. Front Oncol 2021;11:670415. [PMID: 34221986 DOI: 10.3389/fonc.2021.670415] [Reference Citation Analysis]
9 Cañete F, Mañosa M, Lobatón T, Mesonero F, Rodríguez-Lago I, Cabré E, Cabriada JL, López-Sanromán A, Domènech E. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature. Int J Colorectal Dis 2019;34:861-5. [PMID: 30826963 DOI: 10.1007/s00384-019-03268-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ibraheim H, Baillie S, Samaan MA, Abu-Sbeih H, Wang Y, Talley NJ, P Jones M, Powell N. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020;52:1432-52. [PMID: 32920854 DOI: 10.1111/apt.15998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
11 Triggianese P, Novelli L, Galdiero MR, Chimenti MS, Conigliaro P, Perricone R, Perricone C, Gerli R. Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmun Rev 2020;19:102590. [PMID: 32561463 DOI: 10.1016/j.autrev.2020.102590] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
12 Mohamed AA, Richards CJ, Boyle K, Faust G. Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma. BMJ Case Rep 2018;2018:bcr-2018-224913. [PMID: 29622719 DOI: 10.1136/bcr-2018-224913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
13 Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer 2019;19:379. [PMID: 31018834 DOI: 10.1186/s12885-019-5577-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Abu-Sbeih H, Wang Y. Gastrointestinal Tract Adverse Events. Adv Exp Med Biol 2020;1244:247-53. [PMID: 32301019 DOI: 10.1007/978-3-030-41008-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Oncologist 2019;24:1128-36. [PMID: 31015312 DOI: 10.1634/theoncologist.2018-0563] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
16 Boussios S, Sheriff M, Rassy E, Moschetta M, Samartzis EP, Hallit R, Sadauskaite A, Katsanos KH, Christodoulou DK, Pavlidis N. Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Ann Transl Med 2021;9:423. [PMID: 33842644 DOI: 10.21037/atm-20-7361] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology. 2021;160:1384-1393. [PMID: 33080231 DOI: 10.1053/j.gastro.2020.08.063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
18 Sleiman J, Wei W, Shah R, Faisal MS, Philpott J, Funchain P. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study. J Immunother Cancer 2021;9:e002567. [PMID: 34158318 DOI: 10.1136/jitc-2021-002567] [Reference Citation Analysis]
19 Raju S, Joseph R, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther 2018;7:63-75. [PMID: 30105218 DOI: 10.2147/ITT.S125070] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
20 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
21 Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056-67. [DOI: 10.1136/gutjnl-2018-316948] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 24.7] [Reference Citation Analysis]
22 Tran AN, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A, Ciarleglio M, Hung KW, Proctor DD, Price CC, Laine L, Al-Bawardy B. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. J Immunother 2021;44:325-34. [PMID: 34380976 DOI: 10.1097/CJI.0000000000000383] [Reference Citation Analysis]
23 Papouin B, Mussini C, De Martin E, Guettier C. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review]. Ann Pathol 2018;38:338-51. [PMID: 30143243 DOI: 10.1016/j.annpat.2018.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Favara DM, Spain L, Au L, Clark J, Daniels E, Diem S, Chauhan D, Turajlic S, Powell N, Larkin JM, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open. 2020;5. [PMID: 32641348 DOI: 10.1136/esmoopen-2019-000585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
25 Cǎlugǎreanu A, Rompteaux P, Bohelay G, Goldfarb L, Barrau V, Cucherousset N, Heidelberger V, Nault JC, Ziol M, Caux F, Maubec E. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy 2019;11:1005-13. [PMID: 31304833 DOI: 10.2217/imt-2019-0077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Sanz-Segura P, García-Cámara P, Fernández-Bonilla E, Arbonés-Mainar JM, Bernal Monterde V. Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study. Gastroenterol Hepatol 2021;44:261-8. [PMID: 33153772 DOI: 10.1016/j.gastrohep.2020.07.009] [Reference Citation Analysis]
27 Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, Richards DM, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019;54:538-545. [PMID: 31079556 DOI: 10.1080/00365521.2019.1594356] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
28 Isidro RA, Ruan AB, Gannarapu S, Raj D, Rahma O, Grover S, Srivastava A. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology 2021;78:532-41. [PMID: 32931028 DOI: 10.1111/his.14248] [Reference Citation Analysis]
29 Badran YR, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, Kem M, Zheng H, Borowsky J, Misdraji J, Mino-Kenudson M, Dougan M. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer 2020;8:e000958. [PMID: 32581063 DOI: 10.1136/jitc-2020-000958] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
30 Frohne CC, Llano EM, Perkovic A, Cohen RD, Luke JJ. Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies. J Immunother Cancer 2019;7:1. [PMID: 30612589 DOI: 10.1186/s40425-018-0484-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 17] [Article Influence: 22.5] [Reference Citation Analysis]
31 Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol 2020;22:919-27. [PMID: 31576495 DOI: 10.1007/s12094-019-02214-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
32 Hayashi Y, Hosoe N, Takabayashi K, Limpias Kamiya KJL, Tsugaru K, Shimozaki K, Hirata K, Fukuhara K, Fukuhara S, Mutaguchi M, Sujino T, Sukawa Y, Hamamoto Y, Naganuma M, Takaishi H, Shimoda M, Ogata H, Kanai T. Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. Dig Dis Sci. 2021;66:2129-2134. [PMID: 32621258 DOI: 10.1007/s10620-020-06441-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
33 Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020;115:202-210. [PMID: 31922959 DOI: 10.14309/ajg.0000000000000497] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
34 de Malet A, Antoni G, Collins M, Soularue E, Marthey L, Vaysse T, Coutzac C, Chaput N, Mateus C, Robert C, Carbonnel F. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer 2019;106:106-14. [PMID: 30476730 DOI: 10.1016/j.ejca.2018.10.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
35 Alhatem A, Patel K, Eriksen B, Bukhari S, Liu C. Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects. ACG Case Rep J 2019;6:e00249. [PMID: 32309466 DOI: 10.14309/crj.0000000000000249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. WJGO 2021;13:772-98. [DOI: 10.4251/wjgo.v13.i8.772] [Reference Citation Analysis]
37 Andrews S, Ludlow SP. Autonomic enteric neuropathy following nivolumab monotherapy in a patient with Lung Cancer. Current Problems in Cancer: Case Reports 2020;1:100014. [DOI: 10.1016/j.cpccr.2020.100014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - What to do and when? Best Pract Res Clin Gastroenterol 2020;48-49:101703. [PMID: 33317787 DOI: 10.1016/j.bpg.2020.101703] [Reference Citation Analysis]
39 Allard FD, Stelow EB. Review of Drug-induced Injury in Mucosal Biopsies From the Tubular Gastrointestinal Tract. Advances in Anatomic Pathology 2019;26:151-70. [DOI: 10.1097/pap.0000000000000230] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology (Oxford) 2019;58:vii17-28. [PMID: 31816081 DOI: 10.1093/rheumatology/kez465] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
41 Biniakewitz MD, Kasler MK, Fessele KL. Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. Asia Pac J Oncol Nurs 2021;8:18-24. [PMID: 33426185 DOI: 10.4103/apjon.apjon_48_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Lemiale V, Meert AP, Vincent F, Darmon M, Bauer PR, Van de Louw A, Azoulay E; Groupe de Recherche en Reanimation Respiratoire du patient d’Onco-Hématologie (Grrr-OH). Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know? Ann Intensive Care 2019;9:25. [PMID: 30707321 DOI: 10.1186/s13613-019-0487-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
43 Ma C, MacDonald JK, Nguyen TM, Vande Casteele N, Linggi B, Lefevre P, Wang Y, Feagan BG, Jairath V. Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. Dig Dis Sci 2021. [PMID: 33770330 DOI: 10.1007/s10620-021-06948-w] [Reference Citation Analysis]
44 Iranzo I, Huguet JM, Suárez P, Ferrer-Barceló L, Iranzo V, Sempere J. Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity. World J Gastrointest Endosc 2018;10:392-9. [PMID: 30631403 DOI: 10.4253/wjge.v10.i12.392] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
45 Teufel A, Zhan T, Härtel N, Bornschein J, Ebert MP, Schulte N. Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Letters 2019;456:80-7. [DOI: 10.1016/j.canlet.2019.04.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
46 Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, Allen IM, Reynolds KL, Dougan M. Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med 2019;8:4986-99. [PMID: 31286682 DOI: 10.1002/cam4.2397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
47 Appelbaum J, Wells D, Hiatt JB, Steinbach G, Stewart FM, Thomas H, Nghiem P, Kapur RP, Thompson JA, Bhatia S. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 2018;6:82. [PMID: 30170630 DOI: 10.1186/s40425-018-0396-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
48 Kostine M, Marabelle A, Schaeverbeke T, Kfoury M. [Toxicities of immune checkpoint inhibitors and their management]. Med Sci (Paris) 2019;35:949-56. [PMID: 31903899 DOI: 10.1051/medsci/2019191] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Tian Y, Abu-sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Colitis. In: Naing A, Hajjar J, editors. Immunotherapy. Cham: Springer International Publishing; 2018. pp. 151-7. [DOI: 10.1007/978-3-030-02505-2_7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]